Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Survodutide phase 2 (obesity)

Survodutide phase 2 (obesity)

Survodutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Survodutide
Population
obesity
Phase
2
Participants
387
Duration
46 weeks
Registry
NCT04667377

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
survodutide 4.8 mgobesity46387−18.7 % vs −2.3 %
Δ −16.4 pp
−14.9 % vs −2.8 %
Δ −12.1 pp
—29.0 vs 4.039.0 vs 40.364.0 vs 20.035.0 vs 5.05.0 vs 7.0−8.6 vs −2.5verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (8)
  • survodutide 4.8 mg · weight_eff · Results, paragraph 2 and Table 2
    to -18-7% (-20-8 to -16-6; survodutide 4-8 mg) when participants were analysed according to the actual treatment
  • survodutide 4.8 mg · weight_tp · Results, paragraph 2; Abstract; Table 2
    -14-9% (-16-9 to -13-0; survodutide 4-8 mg) versus -2-8% (-4-9 to -0-7) for placebo
  • survodutide 4.8 mg · ae_dc · Results, adverse events paragraph and Table 3
    4-8 mg, 22 [29%] of 77; 0-6 mg, 15 [20%] of 7; 2-4 mg, 20 [26%] of 78; 3-6 mg, 19 [25%] of 77
  • survodutide 4.8 mg · nausea · Table 3
    Nausea” 15 (20%) 26 (34%) 51 (65%) 48 (62%) 49 (64%) 174 (56%)
  • survodutide 4.8 mg · vomiting · Table 3
    Vomiting" 4(5%) 7(9%) 23 (30%) 26 (34%) 27 (35%) 83 27%)
  • survodutide 4.8 mg · sae · Table 3
    Serioust 5(7%) 10%) 2%) 6 (8%) 4 (5%) 33 (4%)
  • survodutide 4.8 mg · sbp · Table 2, planned treatment
    Systolic blood 62 “81 -87 -86 25 37 56 62 62
  • survodutide 4.8 mg · disc_any · Figure 1 (trial profile)
    20 prematurely stopped 22 prematurely stopped 18 prematurelystopped 18 prematurely stopped 22 prematurely stopped

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Survodutide phase 2 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.